Influenza pandemics, organophosphate poisoning, opioid overdose, and exposure to ionizing radiation are representative of the broad spectrum of biological, chemical, and radiological (CBR) threats that can significantly impact public health and national [Read more]
Humanetics Corporation has been awarded a three-year contract valued at approximately $5.4 million from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The contract [Read more]
Boston-based cancer company Partner Therapeutics, Inc. (PTx) has acquired the global rights to develop, manufacture, and commercialize Leukine (sargramostim) from Sanofi. Leukine is an immuno-stimulant that promotes the growth and activation of [Read more]
In support of rapid development of safe and effective radiological/nuclear medical countermeasures for clinical use under emergency situations, the National Institute of Allergy and Infectious Diseases (NIAID) is seeking new or renewal [Read more]
Following the October 2001 confirmation of anthrax in official government mail, a series of screening processes were implemented to safeguard the Pentagon and other Pentagon delegated facilities from biological hazards that might [Read more]
The Biomedical Advanced Research and Development Authority (BARDA) is soliciting proposals for the advanced research and development of medical countermeasures (MCM) as part of the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE). [Read more]
The National Institute of Allergy and Infectious Diseases (NIAID) is soliciting study proposals to evaluate candidate cellular therapies to treat radiation-induced injuries in appropriate in vivo models when administered 24 hours or [Read more]
The National Institute of Allergy and Infectious Diseases (NIAID) will be soliciting proposals under a new Omnibus Broad Agency Announcement (BAA) expected to be formally released on February 21, 2017. The BAA [Read more]
The Defense Threat Reduction Agency recently updated its Broad Agency Announcement (BAA) supporting Fundamental Research to Counter Weapons of Mass Destruction. Issued in March 2015, the BAA is effective through 2024 or [Read more]
Pluristem Therapeutics on Dec. 6 announced a milestone in its development program for PLX-R18, which is being evaluated as a medical countermeasure in the treatment of the hematologic components of Acute Radiation [Read more]
© 2018 STEMAR MEDIA